Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pascaline Boudou-Rouquette

Showing results (51-60 of 122) with videos related to

Pageof 13
Sort By:
JCO Precision Oncology|June 7, 2024
Efficacy and Safety of Immune Checkpoint Blockade in Patients With Li-Fraumeni SyndromeMichele Bottosso, Benjamin Verret, Olivier Caron, et al.
Clinical Nutrition (Edinburgh, Scotland)|February 2, 2017
Resting energy expenditure in the risk assessment of anticancer treatmentsAnne Jouinot, Clara Vazeille, Jean Philippe Durand, et al.
Clinical Nutrition (Edinburgh, Scotland)|April 26, 2023
Impact of sarcopenia indexes on survival and severe immune acute toxicity in metastatic non-small cell lung cancer patients treated with PD-1 immune checkpoint inhibitorsElisabeth Ashton, Jennifer Arrondeau, Anne Jouinot, et al.
Journal of Pharmaceutical and Biomedical Analysis|June 9, 2018
Liquid chromatography-tandem mass spectrometric assay for therapeutic drug monitoring of the EGFR inhibitors afatinib, erlotinib and osimertinib, the ALK inhibitor crizotinib and the VEGFR inhibitor nintedanib in human plasma from non-small cell lung cancer patientsRafael Reis, Laurence Labat, Marie Allard, et al.
Pharmaceutics|June 24, 2022
Relation between Plasma Trough Concentration of Pazopanib and Progression-Free Survival in Metastatic Soft Tissue Sarcoma PatientsMarie-Sophie Minot-This, Pascaline Boudou-Rouquette, Anne Jouinot, et al.
Journal of Translational Medicine|September 19, 2023
Immunologic constant of rejection as a predictive biomarker of immune checkpoint inhibitors efficacy in non-small cell lung cancerAlice Mogenet, Pascal Finetti, Emilie Denicolai, et al.
Cancers|January 11, 2022
Predicting Frailty and Geriatric Interventions in Older Cancer Patients: Performance of Two Screening Tools for Seven Frailty Definitions-ELCAPA CohortClaudia Martinez-Tapia, Marie Laurent, Elena Paillaud, et al.
Journal of Medical Genetics|October 25, 2018
Chemoresistant pleomorphic rhabdomyosarcoma: whole exome sequencing reveals underlying cancer predisposition and therapeutic optionsCamille Tlemsani, Karen Leroy, Anne-Paule Gimenez-Roqueplo, et al.
Clinical Nutrition (Edinburgh, Scotland)|August 15, 2025
Early nutritional and inflammation assessment predicts prognosis in patients with cancer across tumor origin and metastatic statusJuliette Renard, Jean-Philippe Durand, Sixtine De Percin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 24, 2025
Machine Learning to Predict Mortality in Older Patients With Cancer: Development and External Validation of the Geriatric Cancer Scoring System Using Two Large French CohortsEtienne Audureau, Pierre Soubeyran, Claudia Martinez-Tapia, et al.
Pageof 13

Showing results (51-60 of 122) with videos related to

Sort By:
Pageof 13
JCO Precision Oncology|June 7, 2024
Efficacy and Safety of Immune Checkpoint Blockade in Patients With Li-Fraumeni SyndromeMichele Bottosso, Benjamin Verret, Olivier Caron, et al.
Clinical Nutrition (Edinburgh, Scotland)|February 2, 2017
Resting energy expenditure in the risk assessment of anticancer treatmentsAnne Jouinot, Clara Vazeille, Jean Philippe Durand, et al.
Clinical Nutrition (Edinburgh, Scotland)|April 26, 2023
Impact of sarcopenia indexes on survival and severe immune acute toxicity in metastatic non-small cell lung cancer patients treated with PD-1 immune checkpoint inhibitorsElisabeth Ashton, Jennifer Arrondeau, Anne Jouinot, et al.
Journal of Pharmaceutical and Biomedical Analysis|June 9, 2018
Liquid chromatography-tandem mass spectrometric assay for therapeutic drug monitoring of the EGFR inhibitors afatinib, erlotinib and osimertinib, the ALK inhibitor crizotinib and the VEGFR inhibitor nintedanib in human plasma from non-small cell lung cancer patientsRafael Reis, Laurence Labat, Marie Allard, et al.
Pharmaceutics|June 24, 2022
Relation between Plasma Trough Concentration of Pazopanib and Progression-Free Survival in Metastatic Soft Tissue Sarcoma PatientsMarie-Sophie Minot-This, Pascaline Boudou-Rouquette, Anne Jouinot, et al.
Journal of Translational Medicine|September 19, 2023
Immunologic constant of rejection as a predictive biomarker of immune checkpoint inhibitors efficacy in non-small cell lung cancerAlice Mogenet, Pascal Finetti, Emilie Denicolai, et al.
Cancers|January 11, 2022
Predicting Frailty and Geriatric Interventions in Older Cancer Patients: Performance of Two Screening Tools for Seven Frailty Definitions-ELCAPA CohortClaudia Martinez-Tapia, Marie Laurent, Elena Paillaud, et al.
Journal of Medical Genetics|October 25, 2018
Chemoresistant pleomorphic rhabdomyosarcoma: whole exome sequencing reveals underlying cancer predisposition and therapeutic optionsCamille Tlemsani, Karen Leroy, Anne-Paule Gimenez-Roqueplo, et al.
Clinical Nutrition (Edinburgh, Scotland)|August 15, 2025
Early nutritional and inflammation assessment predicts prognosis in patients with cancer across tumor origin and metastatic statusJuliette Renard, Jean-Philippe Durand, Sixtine De Percin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 24, 2025
Machine Learning to Predict Mortality in Older Patients With Cancer: Development and External Validation of the Geriatric Cancer Scoring System Using Two Large French CohortsEtienne Audureau, Pierre Soubeyran, Claudia Martinez-Tapia, et al.
Pageof 13